A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical
study in adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Patients will be treated with the combination of copanlisib and rucaparib for as long as the
patient does not have clinically significant progressive disease and/or unacceptable toxicity
and/or as long as the investigator deems that the patient is benefiting from treatment.
Treatment may also be stopped if the patient withdraws consent, or study termination occurs.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Brown University
Collaborators:
Bayer Clovis Oncology, Inc. Rhode Island Hospital The Miriam Hospital